Millie
your market intelligence analyst
Search Results
17 results
Your search is now limited to «Inflammation» expert search.
Disease Models & Mechanisms 12/16/2019 03:24
ABSTRACT. Tendon disorders frequently occur and recent evidence has clearly implicated the presence of immune cells and inflammatory events during early tendinopathy. However, the origin and properties of these cells remain poorly defined. Therefore, the aim of this study was to determine the presence of cells in healthy rodent and human tendon tissue fulfilling macrophage-like functions. Using various transgenic reporter mouse models, we demonstrate the presence of tendon-resident cells in the dense matrix of the tendon core expressing the fractalkine (Fkn) receptor CX3CR1 and its cognate ligand CX3CL1/Fkn. Pro-inflammatory stimulation of 3D tendon-like constructs in vitro resulted in a significant increase in the expression of IL-1β, IL-6,
FeedNavigator (EU) 12/13/2019 02:07
Objective: This study aimed to identify the risk factors for a rapid decline in the estimated glomerular filtration rate (eGFR) in Chinese patients with type 2 diabetes and biopsy-proven diabetic kidney disease (DKD). Method: This was a retrospective cohort study. Patients with biopsy-proven DKD who had been followed-up for at least 1 year were enrolled. Baseline clinicopathological data and serum creatinine levels that had been measured at least three times during follow-up in our hospital were collected. Patients were allocated to two groups of rapid decliners and slow decliners according to the median eGFR slope. The associations between potential risk factors and rapid eGFR decline were analyzed using logistic regression. Results: A tot.
Healio News 12/11/2019 13:50
LEO Pharma announced that tralokinumab met all primary and secondary endpoints in ECZTRA 1-3, its three pivotal phase 3 studies for moderate to severe atopic dermatitis in adults. “AD is the most common inflammatory skin disease in the world with limited effective treatment options, especially for moderate to severe patients. We are encouraged that tralokinumab could potentially offer a new long-term treatment for the moderate to severe patient with AD,” Catherine Mazzacco, CEO at LEO Pharma, told Healio in an interview. Tralokinumab is an investigational, fully human monoclonal.
PROVIDENCE, R.I. (AP) - Researchers at Brown University and two Rhode Island hospitals announced they are researching a new drug to treat Alzheimer's disease. Brown, Butler Hospital and The Miriam Hospital are starting a phase-one clinical trial of emtricitabine, the three institutions announced Monday. The drug, sold under the name ...

Personal Care

Household Products

Business Issues

Trends

Companies - Public

Companies - Venture Funded

Information Technologies

Regions

Job Titles